Michael Trauner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3005934/publications.pdf

Version: 2024-02-01

579 papers	42,624 citations	1994 101 h-index	3732 179 g-index
668 all docs	668 docs citations	668 times ranked	37838 citing authors

#	Article	IF	Citations
1	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	17.8	964
2	Detection of Various Microplastics in Human Stool. Annals of Internal Medicine, 2019, 171, 453-457.	3.9	939
3	Bile Salt Transporters: Molecular Characterization, Function, and Regulation. Physiological Reviews, 2003, 83, 633-671.	28.8	873
4	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
5	The interaction of hepatic lipid and glucose metabolism in liver diseases. Journal of Hepatology, 2012, 56, 952-964.	3.7	728
6	Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. Gastroenterology, 2007, 132, 330-342.	1.3	725
7	Molecular Pathogenesis of Cholestasis. New England Journal of Medicine, 1998, 339, 1217-1227.	27.0	719
8	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. Annals of Internal Medicine, 2020, 173, 350-361.	3.9	653
9	ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-Î± and PGC-1. Nature Medicine, 2011, 17, 1076-1085.	30.7	612
10	Bile acid receptors as targets for drug development. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 55-67.	17.8	565
11	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 2004, 127, 261-274.	1.3	525
12	Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia. Science, 2011, 333, 233-238.	12.6	475
13	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	1.3	470
14	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology, 2017, 65, 350-362.	7.3	444
15	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. Journal of Hepatology, 2015, 62, S25-S37.	3.7	406
16	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 321-350.	22.4	387
17	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	1.3	355
18	Nonselective Î² Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology, 2014, 146, 1680-1690.e1.	1.3	336

#	Article	IF	Citations
19	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
20	Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology, 2001, 33, 633-646.	7.3	324
21	Targeting the gut-liver axis in liver disease. Journal of Hepatology, 2017, 67, 1084-1103.	3.7	311
22	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. Journal of Hepatology, 2013, 58, 155-168.	3.7	304
23	Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development. Toxicological Sciences, 2010, 118, 485-500.	3.1	302
24	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology, 2005, 42, 420-430.	7.3	295
25	A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis. American Journal of Pathology, 2007, 171, 525-536.	3.8	293
26	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLARÂtrials. Journal of Hepatology, 2020, 73, 26-39.	3.7	290
27	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis:Â Pathogenetic and Therapeutic Considerations. Molecular Pharmaceutics, 2006, 3, 231-251.	4.6	288
28	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 2013, 57, 2261-2273.	7.3	288
29	Ursodeoxycholic acid aggravates bile infarcts in bile ductâ€“ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology, 2002, 123, 1238-1251.	1.3	287
30	24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice. Gastroenterology, 2006, 130, 465-481.	1.3	282
31	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 283-308.	4.1	275
32	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62, 1634-1641.	12.1	275
33	Pathophysiological mechanisms of liver injury in COVIDâ€19. Liver International, 2021, 41, 20-32.	3.9	273
34	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. Journal of Hepatology, 2013, 58, 911-921.	3.7	269
35	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. Gastroenterology, 2005, 129, 476-485.	1.3	268
36	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. Journal of Hepatology, 2003, 38, 717-727.	3.7	260

#	Article	IF	Citations
37	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTÎ±-OSTÎ² in cholestasis in humans and rodents. American Journal of Physiology - Renal Physiology, 2006, 290, G1124-G1130.	3.4	255
38	Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse Liver. Gastroenterology, 2001, 121, 170-183.	1.3	254
39	Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism. Digestive Diseases, 2010, 28, 220-224.	1.9	254
40	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology, 2003, 125, 825-838.	1.3	252
41	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of Hepatology, 2016, 65, 692-699.	3.7	245
42	Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis. Gastroenterology, 2012, 142, 355-365.e4.	1.3	243
43	New molecular insights into the mechanisms of cholestasis. Journal of Hepatology, 2009, 51, 565-580.	3.7	241
44	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology, 2000, 118, 163-172.	1.3	240
45	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. Journal of Hepatology, 2015, 62, 1398-1404.	3.7	236
46	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. Gastroenterology, 2005, 129, 476-485.	1.3	235
47	Fatty liver and lipotoxicity. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 299-310.	2.4	232
48	Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. Journal of Hepatology, 2005, 43, 1045-1054.	3.7	228
49	Nuclear receptors in liver disease. Hepatology, 2011, 53, 1023-1034.	7.3	226
50	Sex-Specific Prevalence of Adenomas, Advanced Adenomas, and Colorectal Cancer in Individuals Undergoing Screening Colonoscopy. JAMA - Journal of the American Medical Association, 2011, 306, 1352.	7.4	225
51	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. Journal of Hepatology, 2003, 38, 419-425.	3.7	221
52	Inflammation-induced cholestasis. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 946-959.	2.8	206
53	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	3.7	202
54	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinomaÂformation. Nature Cell Biology, 2014, 16, 972-981.	10.3	198

#	Article	IF	Citations
55	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology, 2019, 70, 1521-1530.	7.3	197
56	Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. Journal of Hepatology, 2016, 65, 856-858.	3.7	196
57	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
58	Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016, 1, e000042.	4.5	194
59	Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 574-585.	1.7	193
60	Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 ^{â˜'/â˜'} (Abcb4 ^{â˜'/â˜'}) mouse cholangiopathy model by promoting biliary HCOâ€‰3â˜' output. Hepatology, 2011, 54, 1303-1312.	7.3	193
61	MDR3 (ABCB4) Defects: A Paradigm for the Genetics of Adult Cholestatic Syndromes. Seminars in Liver Disease, 2007, 27, 077-098.	3.6	188
62	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 788-801.	7.3	180
63	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology, 2017, 65, 1875-1890.	7.3	177
64	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. Journal of Hepatology, 2003, 39, 480-488.	3.7	171
65	Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 854-860.	2.4	168
66	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology, 2017, 65, 1393-1404.	7.3	167
67	Mechanisms of Cholestasis. Clinics in Liver Disease, 2008, 12, 1-26.	2.1	166
68	Lithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice. American Journal of Pathology, 2006, 168, 410-422.	3.8	161
69	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology, 2012, 56, 1439-1447.	7.3	158
70	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
71	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Scientific Reports, 2018, 8, 6220.	3.3	155
72	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-Î±/Î² in the adaptive response to bile acids. American Journal of Physiology - Renal Physiology, 2006, 290, G923-G932.	3.4	154

#	Article	IF	Citations
73	Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts. American Journal of Pathology, 2009, 175, 2392-2405.	3.8	154
74	Liver Dysfunction and Phosphatidylinositol-3-Kinase Signalling in Early Sepsis: Experimental Studies in Rodent Models of Peritonitis. PLoS Medicine, 2012, 9, e1001338.	8.4	152
75	Molecular regulation of hepatocellular transport systems in cholestasis. Journal of Hepatology, 1999, 31, 165-178.	3.7	148
76	Spontaneous cholecysto- and hepatolithiasis inMdr2?/? mice: A model for low phospholipid-associated cholelithiasis. Hepatology, 2004, 39, 117-128.	7.3	148
77	Molecular Regulation of Hepatobiliary Transport Systems. Journal of Clinical Gastroenterology, 2005, 39, S111-S124.	2.2	148
78	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology, 2016, 64, 556-568.	7.3	148
79	In vivo quantification of liver dialysis: Comparison of albumin dialysis and fractionated plasma separation. Journal of Hepatology, 2005, 43, 451-457.	3.7	146
80	Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort. Clinical Gastroenterology and Hepatology, 2014, 12, 683-689.	4.4	146
81	Nuclear receptors as therapeutic targets in cholestatic liver diseases. British Journal of Pharmacology, 2009, 156, 7-27.	5.4	143
82	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. Journal of Hepatology, 2016, 64, 674-681.	3.7	143
83	Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury. Gastroenterology, 2012, 142, 140-151.e12.	1.3	139
84	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 1287-1296.	3.7	139
85	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2â^'/â^' mice. Hepatology, 2009, 49, 1972-1981.	7.3	135
86	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology, 2016, 63, 1357-1367.	7.3	133
87	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy â€“ development and validation of the CRAFITY score. Journal of Hepatology, 2022, 76, 353-363.	3.7	132
88	Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology, 2013, 58, 2056-2069.	7.3	130
89	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of Hepatology, 2017, 66, 724-733.	3.7	130
90	Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 2014, 60, 1290-1303.	3.7	129

#	Article	IF	Citations
91	The keratin cytoskeleton in liver diseases. Journal of Pathology, 2004, 204, 367-376.	4.5	121
92	Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. Journal of Lipid Research, 2009, 50, 312-326.	4.2	121
93	Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 432-450.	17.8	119
94	Hepatotoxicity of NONI juice: Report of two cases. World Journal of Gastroenterology, 2005, 11, 4758.	3.3	118
95	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 511-523.	2.8	116
96	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology and Hepatology, 2019, 4, 445-453.	8.1	116
97	Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4â€“NF-ÎºBâ€”Mediated Inflammatory Response in Mice. Gastroenterology, 2011, 141, 1498-1508.e5.	1.3	114
98	Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver International, 2005, 25, 367-379.	3.9	112
99	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferonâ€Free Therapy. Hepatology, 2020, 71, 1023-1036.	7.3	112
100	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver International, 2015, 35, 381-390.	3.9	111
101	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothÂIII). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.9	111
102	Programmed cell death proteinâ€1 (<scp>PD</scp>â€1)â€targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	3.7	106
103	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. Journal of Hepatology, 2014, 60, 118-126.	3.7	105
104	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology, 2014, 59, 1972-1983.	7.3	105
105	Pathogenesis of primary sclerosing cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 727-739.	2.4	104
106	Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver International, 2007, 27, 920-929.	3.9	103
107	Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wiener Medizinische Wochenschrift, 2008, 158, 542-548.	1.1	102
108	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102

#	Article	IF	Citations
109	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology, 2013, 57, 2224-2234.	7.3	101
110	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. Hepatology, 2021, 74, 133-147.	7.3	101
111	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
112	Fxrâ^'/â^' mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. Journal of Lipid Research, 2006, 47, 582-592.	4.2	98
113	Association of 25â€hydroxyvitamin <scp>D</scp> levels with liver dysfunction and mortality in chronic liver disease. Liver International, 2012, 32, 845-851.	3.9	97
114	Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis. PLoS ONE, 2012, 7, e46584.	2.5	97
115	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. Journal of Hepatology, 2021, 74, 819-828.	3.7	96
116	Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acidâ€“enhanced MR Imaging. Radiology, 2015, 277, 104-113.	7.3	95
117	Molecular aspects of bile formation and cholestasis. Trends in Molecular Medicine, 2003, 9, 558-564.	6.7	94
118	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. American Journal of Physiology - Renal Physiology, 2005, 289, G831-G841.	3.4	94
119	Nuclear Receptors as New Perspective for the Management of Liver Diseases. Gastroenterology, 2011, 140, 1120-1125.e12.	1.3	94
120	Noninvasive screening for liver fibrosis and portal hypertension by transient elastographyâ€”a large single center experience. Wiener Klinische Wochenschrift, 2012, 124, 395-402.	1.9	93
121	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. Cell Metabolism, 2014, 20, 787-798.	16.2	92
122	Farnesoid X receptor represses hepatic human APOA gene expression. Journal of Clinical Investigation, 2011, 121, 3724-3734.	8.2	92
123	Nuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis. Seminars in Liver Disease, 2010, 30, 160-177.	3.6	90
124	Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 343-353.	2.8	89
125	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism: Clinical and Experimental, 2014, 63, 1542-1552.	3.4	88
126	Liver Injury and Failure in Critical Illness. Hepatology, 2019, 70, 2204-2215.	7.3	88

#	Article	IF	Citations
127	Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. Clinics in Liver Disease, 2013, 17, 161-189.	2.1	87
128	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology, 2015, 89, 2089-2103.	4.2	86
129	The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity, 2019, 105, 102328.	6.5	86
130	Hepatic steatosis in Wilson disease â€“ Role of copper and PNPLA3 mutations. Journal of Hepatology, 2015, 63, 156-163.	3.7	85
131	Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. Journal of Hepatology, 2013, 58, 1201-1208.	3.7	84
132	Novel therapeutic targets for cholestatic and fatty liver disease. Gut, 2022, 71, 194-209.	12.1	84
133	EASL Clinical Practice Guidelines on sclerosing cholangitis. Journal of Hepatology, 2022, 77, 761-806.	3.7	84
134	Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut, 2010, 59, 521-530.	12.1	83
135	Lactate Improves Prediction of Shortâ€Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. Hepatology, 2019, 69, 258-269.	7.3	83
136	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology, 2019, 157, 705-719.e18.	1.3	82
137	Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. Toxicology Letters, 2014, 228, 56-66.	0.8	81
138	Oncosis represents the main type of cell death in mouse models of cholestasis. Journal of Hepatology, 2005, 42, 378-385.	3.7	80
139	Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. International Journal of Cancer, 2012, 130, 2232-2239.	5.1	80
140	Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology, 2014, 59, 858-869.	7.3	80
141	Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2016, 36, 069-086.	3.6	80
142	Cystic Fibrosisâ€“related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 443-448.	1.8	80
143	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, 126, 228-243.		79
144	Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology, 2007, 46, 776-784.	7.3	77

#	Article	IF	Citations
145	Sedation in Screening Colonoscopy: Impact on Quality Indicators And Complications. American Journal of Gastroenterology, 2012, 107, 1837-1848.	0.4	77
146	Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 867-878.	3.8	75
147	Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. Hepatology, 2012, 56, 270-280.	7.3	75
148	Hypoxic liver injury and cholestasis in critically ill patients. Current Opinion in Critical Care, 2013, 19, 128-132.	3.2	75
149	A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. Psychosomatic Medicine, 2018, 80, 698-709.	2.0	75
150	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 585-592.	2.8	74
151	Bile acids induce arrhythmias in human atrial myocardiumâ€"implications for altered serum bile acid composition in patients with atrial fibrillation. Heart, 2013, 99, 1685-1692.	2.9	73
152	The liver in sepsis. Current Opinion in Critical Care, 2013, 19, 123-127.	3.2	73
153	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International, 2016, 29, 999-1007.	1.6	73
154	Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. Journal of Hepatology, 1997, 27, 163-169.	3.7	72
155	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver International, 2015, 35, 2121-2128.	3.9	72
156	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. Immunity, 2019, 51, 1074-1087.e9.	14.3	72
157	Signal Transducer and Activator of Transcription 3 Protects From Liver Injury and Fibrosis in a Mouse Model of Sclerosing Cholangitis. Gastroenterology, 2010, 138, 2499-2508.	1.3	71
158	Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends in Endocrinology and Metabolism, 2014, 25, 576-585.	7.1	71
159	Inflammatory Bowel Disease Alters Intestinal Bile Acid Transporter Expression. Drug Metabolism and Disposition, 2014, 42, 1423-1431.	3.3	70
160	Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoxetic Acidâ€"enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. Radiology, 2014, 271, 739-747.	7.3	70
161	Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology, 1998, 28, 1081-1087.	7.3	68
162	Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. Hepatology, 2012, 56, 2297-2304.	7.3	68

#	Article	IF	Citations
163	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clinical and Translational Gastroenterology, 2020, 11, e00131.	2.5	68
164	Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 77, 918-930.	3.7	68
165	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. American Journal of Physiology - Renal Physiology, 2005, 289, G798-G805.	3.4	67
166	Acid-base disorders in liver disease. Journal of Hepatology, 2017, 67, 1062-1073.	3.7	67
167	Gut-liver axis signaling in portal hypertension. World Journal of Gastroenterology, 2019, 25, 5897-5917.	3.3	67
168	Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. American Journal of Physiology - Renal Physiology, 2002, 282, G184-G191.	3.4	66
169	Role of adipose tissue in methionineâ€“choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 959-970.	3.8	66
170	Fibrosis in Autoimmune and Cholestatic Liver Disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 245-258.	2.4	65
171	The Role of Canalicular ABC Transporters in Cholestasis. Drug Metabolism and Disposition, 2014, 42, 546-560.	3.3	65
172	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2552-2560.e10.	4.4	65
173	Diet and exercise in NAFLD/NASH: Beyond the obvious. Liver International, 2021, 41, 2249-2268.	3.9	64
174	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. Journal of Hepatology, 2022, 76, 841-849.	3.7	64
175	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ^—Z Variant of AAT (Piâ^—MZ vs) Tj ETQq1 1 0.784314 rgB	1.3	63
176	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes, 2018, 67, 2541-2553.	0.6	60
177	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Gastroenterology, 2021, 160, 1608-1619.e13.	1.3	60
178	Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. Journal of Hepatology, 2022, 77, 1373-1385.	3.7	60
179	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut, 2019, 68, 522-532.	12.1	59
180	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, 76, 812-821.	3.7	59

#	Article	IF	Citations
181	PNPLA3 expression and its impact on the liver: current perspectives. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 55-66.	2.5	58
182	Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversalâ€"a Case Series. Obesity Surgery, 2018, 28, 812-819.	2.1	58
183	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 781-793.	8.1	58
184	Molecular mechanisms of cholestasis. Wiener Medizinische Wochenschrift, 2006, 156, 380-385.	1.1	57
185	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2011, 9, 602-608.e1.	4.4	57
186	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	4.4	57
187	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. Journal of Hepatology, 2020, 73, 651-663.	3.7	57
188	Will we ever model PSC? â€“ â€œIt's hard to be a PSC model!â€• Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 792-804.	1.5	56
189	Current treatment of nonâ€alcoholic fatty liver disease. Journal of Internal Medicine, 2022, 292, 190-204.	6.0	56
190	Bile Acid-Mediated Control of Liver Triglycerides. Seminars in Liver Disease, 2013, 33, 330-342.	3.6	55
191	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. Journal of Hepatology, 2015, 62, 871-878.	3.7	55
192	Renal replacement therapy in critically ill liver cirrhotic patientsâ€"outcome and clinical implications. Liver International, 2017, 37, 843-850.	3.9	55
193	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterology Journal, 2019, 7, 1113-1123.	3.8	55
194	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. PLoS ONE, 2014, 9, e110503.	2.5	55
195	Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology, 2012, 56, 1883-1891.	7.3	54
196	Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?. Journal of Magnetic Resonance Imaging, 2017, 45, 646-659.	3.4	54
197	A little orphan runs to fat: The orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. Hepatology, 2007, 46, 1-5.	7.3	53
198	Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2^{â^'/â^'} mice by modulating composition, signalling and excretion of faecal bile acids. Gut, 2018, 67, 1683-1691.	12.1	53

#	Article	IF	Citations
199	Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. Toxicology Letters, 2014, 224, 186-195.	0.8	52
200	Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. Cell Systems, 2018, 6, 709-721.e6.	6.2	52
201	Validated Comprehensive Analytical Method for Quantification of Coenzyme A Activated Compounds in Biological Tissues by Online Solid-Phase Extraction LC/MS/MS. Analytical Chemistry, 2008, 80, 5736-5742.	6.5	51
202	Metabolic preconditioning protects BSEP/ABCB11â^'/â^' mice against cholestatic liver injury. Journal of Hepatology, 2017, 66, 95-101.	3.7	51
203	Followâ€up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirinâ€free treatment. Liver International, 2018, 38, 1028-1035.	3.9	51
204	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut, 2021, 70, 1758-1767.	12.1	51
205	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. Journal of Hepatology, 2021, 75, 634-646.	3.7	51
206	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. Journal of Visualized Experiments, 2020, , .	0.3	51
207	Removal of Bile Acids by Two Different Extracorporeal Liver Support Systems in Acute-on-Chronic Liver Failure. ASAIO Journal, 2007, 53, 187-193.	1.6	50
208	Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis, 2010, 209, 178-183.	0.8	50
209	Clinical application of transcriptional activators of bile salt transporters. Molecular Aspects of Medicine, 2014, 37, 57-76.	6.4	50
210	Na+â€taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Hepatology, 2018, 68, 1057-1069.	7.3	50
211	Review article: therapeutic aspects of bile acid signalling in the gutâ€liver axis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1243-1262.	3.7	50
212	Circulating bile acids predict outcome in critically ill patients. Annals of Intensive Care, 2017, 7, 48.	4.6	49
213	Use of inhibitors of the reninâ€“angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2017, 5, 987-996.	3.8	49
214	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget, 2017, 8, 46234-46248.	1.8	49
215	Bile acids in regulation of inflammation and immunity: friend or foe?. Clinical and Experimental Rheumatology, 2016, 34, 25-31.	0.8	49
216	Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. Gastrointestinal Endoscopy, 1995, 42, 416-419.	1.0	48

#	Article	IF	Citations
217	Disruption of the growth hormone-Signal transducer and activator of transcription 5-Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology, 2010, 51, 1319-1326.	7.3	48
218	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Journal of Hepatology, 2012, 57, 492-498.	3.7	48
219	Bile Acid-Induced Cholemic Nephropathy. Digestive Diseases, 2015, 33, 367-375.	1.9	48
220	Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. Obesity Surgery, 2016, 26, 2425-2432.	2.1	48
221	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 203-217.	7.7	48
222	Serum bile acids as marker for acute decompensation and acuteâ€onâ€chronic liver failure in patients with nonâ€cholestatic cirrhosis. Liver International, 2017, 37, 224-231.	3.9	47
223	The value of different CTâ€based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver International, 2019, 39, 2374-2385.	3.9	47
224	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. Journal of Hepatology, 2020, 72, 1122-1131.	3.7	47
225	Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. Journal of Hepatology, 2003, 38, 387-394.	3.7	46
226	Cystic Fibrosis Related Liver Diseaseâ€"Another Black Box in Hepatology. International Journal of Molecular Sciences, 2014, 15, 13529-13549.	4.1	46
227	Recent advances in understanding and managing cholestasis. F1000Research, 2016, 5, 705.	1.6	46
228	Responseâ€guided longâ€term treatment of chronic hepatitis D patients with bulevirtideâ€"results of a â€œreal worldâ€•study. Alimentary Pharmacology and Therapeutics, 2022, 56, 144-154.	3.7	46
229	The Importance of Serum Bile Acid Level Analysis and Treatment With Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy. Archives of Dermatology, 2007, 143, 757-62.	1.4	45
230	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. EBioMedicine, 2016, 11, 58-67.	6.1	45
231	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver International, 2020, 40, 194-204.	3.9	45
232	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology, 2021, 73, 1275-1289.	7.3	45
233	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology, 2022, 75, 1235-1246.	7.3	45
234	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVIDâ€19 in patients with chronic liver disease. Hepatology, 2022, 76, 1563-1575.	7.3	45

#	Article	IF	Citations
235	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. Journal of Hepatology, 2017, 67, 110-119.	3.7	44
236	Low 25-OH-vitaminÂD levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener Klinische Wochenschrift, 2017, 129, 8-15.	1.9	44
237	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. Journal of Hepatology, 2019, 71, 986-991.	3.7	44
238	Bile Acid-Induced Mallory Body Formation in Drug-Primed Mouse Liver. American Journal of Pathology, 2002, 161, 2019-2026.	3.8	43
239	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wiener Klinische Wochenschrift, 2013, 125, 200-219.	1.9	43
240	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. Journal of Hepatology, 2014, 61, 544-549.	3.7	43
241	From the origin of NASH to the future of metabolic fatty liver disease. Gut, 2021, 70, 1570-1579.	12.1	43
242	Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis. Annals of Hepatology, 2005, 4, 77-99.	1.5	42
243	Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiographyâ€"The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis, 2010, 208, 564-571.	0.8	42
244	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. Aids, 2016, 30, 1039-1047.	2.2	42
245	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, 85-90.	1.8	41
246	Multicenter analysis of soluble <scp>A</scp>xl reveals diagnostic value for very early stage hepatocellular carcinoma. International Journal of Cancer, 2015, 137, 385-394.	5.1	41
247	Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. Digestive Diseases, 2016, 34, 580-588.	1.9	41
248	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wiener Klinische Wochenschrift, 2018, 130, 446-455.	1.9	41
249	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes, 2021, 12, 645.	2.4	41
250	Cytokeratins as Targets for Bile Acid-Induced Toxicity. American Journal of Pathology, 2002, 160, 491-499.	3.8	40
251	Cytokine-independent repression of rodentNtcp in obstructive cholestasis. Hepatology, 2005, 41, 470-477.	7.3	40
252	The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. Obesity Surgery, 2016, 26, 2204-2212.	2.1	40

#	Article	IF	Citations
253	E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. Developmental Cell, 2020, 52, 335-349.e7.	7.0	40
254	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4^{-/-}mouse model. World Journal of Hepatology, 2016, 8, 401.	2.0	40
255	Down-regulation of the Na + /taurocholate cotransporting polypeptide during pregnancy in the rat. Journal of Hepatology, 2003, 38, 148-155.	3.7	39
256	Low vitamin D levels are associated with impaired virologic response to PEGIFNâ€Š+â€ŠRBV therapy in HIVâ€“hepatitis C virus coinfected patients. Aids, 2013, 27, 227-232.	2.2	39
257	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Journal of Hepatology, 2014, 60, 1135-1142.	3.7	39
258	Indications for liver transplantation in adults. Wiener Klinische Wochenschrift, 2016, 128, 679-690.	1.9	39
259	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Scientific Reports, 2018, 8, 9372.	3.3	39
260	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver International, 2019, 39, 127-135.	3.9	39
261	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clinical Gastroenterology and Hepatology, 2022, 20, 1362-1373.e6.	4.4	39
262	The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Laboratory Investigation, 2010, 90, 844-852.	3.7	38
263	Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut, 2011, 60, 387-396.	12.1	38
264	Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Laboratory Investigation, 2012, 92, 857-867.	3.7	38
265	Potential of <i>nor</i>-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. Digestive Diseases, 2015, 33, 433-439.	1.9	38
266	Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-ÎºB: New insights into hepatic inflammation. Hepatology, 2008, 48, 1383-1386.	7.3	37
267	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1657-1665.	2.8	37
268	1,25-(OH)2-vitamin D3 prevents activation of hepatic stellate cells inÂvitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4â^'/â^' model. Biochemical and Biophysical Research Communications, 2015, 459, 227-233.	2.1	37
269	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 2021, 9, 60.	3.2	37
270	No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. American Journal of Gastroenterology, 2001, 96, 2286-2287.	0.4	36

#	Article	IF	Citations
271	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology, 2010, 52, 1758-1768.	7.3	36
272	Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology, 2014, 30, 279-286.	2.3	36
273	Safety of direct oral anticoagulants in patients with advanced liver disease. Liver International, 2021, 41, 2159-2170.	3.9	36
274	Healthâ€related quality of life and severity of fatigue in <scp>HIV</scp>/<scp>HCV</scp> coâ€infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver International, 2014, 34, 69-77.	3.9	35
275	Ultraâ€highâ€field magnetic resonance spectroscopy in nonâ€alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in nonâ€alcoholic steatohepatitis and advanced fibrosis. Liver International, 2017, 37, 1544-1553.	3.9	35
276	Liver Transplantation. Investigative Radiology, 2012, 47, 353-358.	6.2	34
277	Assessment of Orthotopic Liver Transplant Graft Survival on Gadoxetic Acidâ€“Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. Investigative Radiology, 2016, 51, 728-734.	6.2	34
278	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease, 2017, 8, e3135-e3135.	6.3	34
279	Evaluation of indocyanine green clearance and model for endâ€stage liver disease for estimation of shortâ€term prognosis in decompensated cirrhosis. Liver International, 2009, 29, 1516-1520.	3.9	33
280	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Digestive Diseases, 2015, 33, 598-607.	1.9	33
281	Fineâ€Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. Hepatology, 2019, 69, 699-716.	7.3	33
282	Pathophysiological Role of Poly(ADP-Ribose) Polymerase (PARP) Activation during Acetaminophen-Induced Liver Cell Necrosis in Mice. Toxicological Sciences, 2005, 84, 201-208.	3.1	32
283	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. Journal of Hepatology, 2006, 44, 243-245.	3.7	32
284	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. Journal of Hepatology, 2011, 55, 876-884.	3.7	32
285	The PPARÎ± agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1555-1565.	2.4	32
286	Revisiting liver disease progression in HIV/HCVâ€coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver International, 2015, 35, 876-885.	3.9	32
287	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2017, 35, 282-287.	1.9	32
288	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233781.	2.5	32

#	Article	IF	Citations
289	Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver International, 2009, 29, 1316-1325.	3.9	31
290	Incidence and mortality trends for biliary tract cancers in Austria. Liver International, 2014, 34, 1102-1108.	3.9	31
291	Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow. Digestive Diseases, 2015, 33, 149-163.	1.9	31
292	Trends in quality of screening colonoscopy in Austria. Endoscopy, 2016, 48, 1102-1109.	1.8	31
293	Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. Digestive Diseases, 2017, 35, 288-292.	1.9	31
294	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver International, 2018, 38, 1427-1436.	3.9	31
295	Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. Journal of Hepatology, 2022, 77, 71-83.	3.7	31
296	Cholestatic syndromes. Current Opinion in Gastroenterology, 2004, 20, 220-230.	2.3	30
297	Outcomes after placement of a SXâ€ŁLLA oesophageal stent for refractory variceal bleedingâ€”A national multicentre study. Liver International, 2019, 39, 290-298.	3.9	30
298	Novel reliability criteria for controlled attenuation parameter assessments for nonâ€invasive evaluation of hepatic steatosis. United European Gastroenterology Journal, 2020, 8, 321-331.	3.8	30
299	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. British Journal of Cancer, 2016, 115, 1421-1429.	6.4	29
300	Vitamin D3 Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial. Obesity Surgery, 2017, 27, 1196-1207.	2.1	29
301	The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease. Hepatology, 2020, 72, 1117-1126.	7.3	29
302	New Insights into Autoimmune Cholangitis through Animal Models. Digestive Diseases, 2010, 28, 99-104.	1.9	28
303	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. Journal of Hepatology, 2014, 60, 1187-1193.	3.7	28
304	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. Annals of Intensive Care, 2016, 6, 61.	4.6	28
305	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. United European Gastroenterology Journal, 2017, 5, 104-110.	3.8	28
306	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease, 2017, 49, 1360-1367.	0.9	28

#	Article	IF	Citations
307	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of Trace Elements in Medicine and Biology, 2017, 39, 100-107.	3.0	28
308	ePTFEâ€TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver International, 2018, 38, 1036-1044.	3.9	28
309	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver International, 2018, 38, 523-531.	3.9	28
310	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	12.1	28
311	Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Seminars in Liver Disease, 2021, 41, 461-475.	3.6	28
312	Nitric oxide and guanosine 3?,5?-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. Hepatology, 1998, 28, 1621-1628.	7.3	27
313	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIVâ€“HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. Antiviral Therapy, 2012, 17, 1327-1334.	1.0	27
314	Application of localized 31P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. European Radiology, 2014, 24, 1602-1609.	4.5	27
315	Growth hormone resistance exacerbates cholestasisâ€induced murine liver fibrosis. Hepatology, 2015, 61, 613-626.	7.3	27
316	Autophagy induced by exogenous bile acids is therapeutic in a model of Î±-1-AT deficiency liver disease. American Journal of Physiology - Renal Physiology, 2016, 311, G156-G165.	3.4	27
317	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. Journal of Hepatology, 2018, 69, 368-377.	3.7	27
318	NorUDCA promotes degradation of Î±1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. PLoS ONE, 2018, 13, e0200897.	2.5	27
319	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. Journal of Lipid Research, 2019, 60, 1284-1292.	4.2	27
320	MRIâ€defined sarcopenia predicts mortality in patients with chronic liver disease. Liver International, 2020, 40, 2797-2807.	3.9	27
321	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver International, 2021, 41, 799-809.	3.9	27
322	Open-label phaseÂII study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. Wiener Klinische Wochenschrift, 2021, 133, 441-451.	1.9	27
323	Primary Sclerosing Cholangitis: New Approaches to Diagnosis, Surveillance and Treatment. Digestive Diseases, 2012, 30, 39-47.	1.9	26
324	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGFâ€A expression in hepatocellular carcinoma. United European Gastroenterology Journal, 2013, 1, 265-275.	3.8	26

#	Article	IF	Citations
325	PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. Hepatology Communications, 2019, 3, 1191-1204.	4.3	26
326	The von Willebrand Factor Facilitates Model for Endâ€Stage Liver Diseaseâ€“Independent Risk Stratification on the Waiting List for Liver Transplantation. Hepatology, 2020, 72, 584-594.	7.3	26
327	COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center. Pathology Research and Practice, 2021, 217, 153305.	2.3	26
328	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology, 2022, 76, 1090-1099.	3.7	26
329	Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. Journal of Hepatology, 1998, 28, 812-819.	3.7	25
330	Hepatic transport systems. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, S105-S112.	2.8	25
331	Evolving concepts in primary sclerosing cholangitis. Liver International, 2012, 32, 352-369.	3.9	25
332	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. Endoscopy, 2015, 47, 207-216.	1.8	25
333	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. Gastrointestinal Endoscopy, 2019, 89, 496-502.	1.0	25
334	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, e251-e266.	4.4	25
335	Hepatocyteâ€specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatinâ€like) Tj ETQq1 1 0.784314 rgBT /Ove 2022, 75, 125-139.	7.3	25
336	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. Oncotarget, 2018, 9, 10054-10068.	1.8	25
337	Targeting Nuclear Bile Acid Receptors for Liver Disease. Digestive Diseases, 2011, 29, 98-102.	1.9	24
338	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis. Journal of Hepatology, 2013, 58, 750-756.	3.7	24
339	Acidâ€“base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Annals of Intensive Care, 2018, 8, 48.	4.6	24
340	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. Cells, 2021, 10, 2516.	4.1	24
341	The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0181878.	2.5	24
342	Extrahepatic cholestasis downregulates Oatp1 by TNFâ€Î± signalling without affecting Oatp2 and Oatp4 expression and sodiumâ€independent bile salt uptake in rat liver. Liver International, 2007, 27, 1056-1065.	3.9	23

#	Article	IF	Citations
343	Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver International, 2008, 28, 948-958.	3.9	23
344	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. Ultrasound in Medicine and Biology, 2015, 41, 2340-2349.	1.5	23
345	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. Endoscopy, 2015, 47, 898-902.	1.8	23
346	The role of TIPS in the management of liver transplant candidates. United European Gastroenterology Journal, 2017, 5, 1100-1107.	3.8	23
347	Liver disease in adults with Î±1â€antitrypsin deficiency. United European Gastroenterology Journal, 2018, 6, 710-718.	3.8	23
348	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Digestive and Liver Disease, 2019, 51, 1144-1151.	0.9	23
349	Nuclear receptors in liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166235.	3.8	23
350	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0143429.	2.5	23
351	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na+/Taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. Hepatology, 1998, 28, 789-795.	7.3	22
352	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. Molecular Pharmaceutics, 2007, 4, 895-910.	4.6	22
353	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. PLoS ONE, 2019, 14, e0216677.	2.5	22
354	High efficacy of interferonâ€free therapy for acute hepatitis C in HIVâ€positive patients. United European Gastroenterology Journal, 2019, 7, 507-516.	3.8	22
355	Optical control of the nuclear bile acid receptor FXR with a photohormone. Chemical Science, 2020, 11, 429-434.	7.4	22
356	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. American Journal of Clinical Nutrition, 2020, 111, 369-377.	4.7	22
357	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acuteâ€onâ€chronic liver failure. United European Gastroenterology Journal, 2021, 9, 427-437.	3.8	22
358	Intra-hepatic haematoma complicating transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome associated with anti-phospholipid antibodies, aplastic anaemia and chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2000, 12, 813-816.	1.6	21
359	Successful conservative management of acute hepatic failure following exertional heatstroke. European Journal of Gastroenterology and Hepatology, 2003, 15, 1135-1139.	1.6	21
360	Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. Journal of Human Genetics, 2012, 57, 564-567.	2.3	21

#	Article	IF	Citations
361	Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 466-473.	2.4	21
362	Adiponectin regulates AQP3 via PPARÎ± in human hepatic stellate cells. Biochemical and Biophysical Research Communications, 2017, 490, 51-54.	2.1	21
363	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver International, 2020, 40, 1415-1426.	3.9	21
364	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver International, 2020, 40, 1098-1110.	3.9	21
365	Serum alkaline phosphatase levels accurately reflect cholestasis in mice. Hepatology, 2015, 62, 981-983.	7.3	20
366	Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. BMC Medicine, 2016, 14, 107.	5.5	20
367	Single-sex infection with female Schistosoma mansoni cercariae mitigates hepatic fibrosis after secondary infection. PLoS Neglected Tropical Diseases, 2017, 11, e0005595.	3.0	20
368	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding â€“ A two decades experience. PLoS ONE, 2018, 13, e0189414.	2.5	20
369	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International, 2020, 40, 393-404.	3.9	20
370	Soluble guanylyl cyclase stimulation and phosphodiesteraseâ€5Âinhibition improve portal hypertension and reduce liver fibrosis in bile ductâ€“ligated rats. United European Gastroenterology Journal, 2020, 8, 1174-1185.	3.8	20
371	Impact of osteopontin on the development of nonâ€alcoholic liver disease and related hepatocellular carcinoma. Liver International, 2020, 40, 1620-1633.	3.9	20
372	24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. Journal of Hepatology, 2021, 75, 1164-1176.	3.7	20
373	The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope?. Hepatology, 2004, 40, 260-263.	7.3	19
374	The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver. Journal of Biological Chemistry, 2010, 285, 1113-1121.	3.4	19
375	Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats. Liver International, 2013, 33, 283-293.	3.9	19
376	Alterations of Canalicular ATP-Binding Cassette Transporter Expression in Drug-Induced Liver Injury. Digestion, 2014, 90, 81-88.	2.3	19
377	Phosphatidylcholine contributes to in vivo 31P MRS signal from the human liver. European Radiology, 2015, 25, 2059-2066.	4.5	19
378	Management of portal hypertension before and after liver transplantation. Liver Transplantation, 2018, 24, 112-121.	2.4	19

#	Article	IF	Citations
379	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model. Laboratory Investigation, 2019, 99, 1906-1917.	3.7	19
380	Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies. Gastrointestinal Endoscopy, 2020, 91, 135-141.	1.0	19
381	Nonâ€invasive diagnosis of cirrhosis and longâ€term disease monitoring by transient elastography in patients with Wilson disease. Liver International, 2020, 40, 894-904.	3.9	19
382	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Reports, 2022, 4, 100513.	4.9	19
383	An In Silico Classification Model for Putative ABCC2 Substrates. Molecular Informatics, 2012, 31, 547-553.	2.5	18
384	Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies. Digestive Diseases, 2014, 32, 631-636.	1.9	18
385	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. Medicine (United States), 2016, 95, e4061.	1.0	18
386	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. European Radiology, 2019, 29, 1048-1058.	4.5	18
387	Shortâ€and longâ€term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 850-858.	3.8	18
388	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Hepatology, 2020, 71, 1750-1765.	7.3	18
389	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. Journal of Gastroenterology, 2020, 55, 533-542.	5.1	18
390	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology, 2022, 75, 610-622.	7.3	18
391	Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Hepatology, 1998, 28, 646-654.	7.3	17
392	When bile ducts say NO: The good, the bad, and the ugly. Gastroenterology, 2003, 124, 847-851.	1.3	17
393	Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy. European Journal of Gastroenterology and Hepatology, 2008, 20, 83-86.	1.6	17
394	Xenobiotic-induced liver injury and fibrosis. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 571-580.	3.3	17
395	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 184-190.	2.8	17
396	The Addition of Câ€Reactive Protein and von Willebrand Factor to Model for Endâ€Stage Liver Diseaseâ€Sodium Improves Prediction of Waitlist Mortality. Hepatology, 2021, 74, 1533-1545.	7.3	17

#	Article	IF	Citations
397	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver International, 2013, 33, 561-568.	3.9	16
398	Role of <scp>FDFT</scp>1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver International, 2014, 34, 388-395.	3.9	16
399	Impact of higher-order heme degradation products on hepatic function and hemodynamics. Journal of Hepatology, 2017, 67, 272-281.	3.7	16
400	Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. United European Gastroenterology Journal, 2018, 6, 1049-1055.	3.8	16
401	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatology Research, 2019, 49, 201-211.	3.4	16
402	Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. Gut, 2021, 70, 1309-1317.	12.1	16
403	COVIDâ€19â€Related Downscaling of Inâ€Hospital Liver Care Decreased Patient Satisfaction and Increased Liverâ€Related Mortality. Hepatology Communications, 2021, 5, 1660-1675.	4.3	16
404	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. PLoS ONE, 2021, 16, e0256544.	2.5	16
405	Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect. PLoS ONE, 2016, 11, e0148210.	2.5	16
406	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. Aids, 2013, 27, 2707-2714.	2.2	15
407	A Greater Proportion of Liver Transplant Candidates Have Colorectal Neoplasia Than in the Healthy Screening Population. Clinical Gastroenterology and Hepatology, 2015, 13, 956-962.	4.4	15
408	Liver Capsule: FXR agonists against liver disease. Hepatology, 2016, 64, 1773-1773.	7.3	15
409	<scp>FXR</scp> controls <scp>CHOP</scp> expression in steatohepatitis. FEBS Letters, 2017, 591, 3360-3368.	2.8	15
410	AQP3 is regulated by PPARÎ³ and JNK in hepatic stellate cells carrying PNPLA3 I148M. Scientific Reports, 2017, 7, 14661.	3.3	15
411	Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5â€“10â€¯mm and 11â€“20â€¯mm. Digestive and Liver Disease, 2019, 51, 536-541.	0.9	15
412	Portal hypertensive gastropathy is associated with iron deficiency anemia. Wiener Klinische Wochenschrift, 2020, 132, 1-11.	1.9	15
413	Loss of bile salt export pump aggravates lipopolysaccharideâ€induced liver injury in mice due to impaired hepatic endotoxin clearance. Hepatology, 2022, 75, 1095-1109.	7.3	15
414	Ageâ€adjusted mortality and predictive value of liver chemistries in a Viennese cohort of <scp>COVID</scp>â€19 patients. Liver International, 2022, 42, 1297-1307.	3.9	15

#	Article	IF	Citations
415	Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test. Medical Oncology, 2014, 31, 151.	2.5	14
416	Pharmacological correction of misfolding of ABC proteins. Drug Discovery Today: Technologies, 2014, 12, e87-e94.	4.0	14
417	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. Annals of Intensive Care, 2015, 5, 47.	4.6	14
418	Effects of Portal Hypertension on Gadoxetic Acidâ€"Enhanced Liver Magnetic Resonance. Investigative Radiology, 2017, 52, 462-469.	6.2	14
419	Non-invasive liver fibrosis assessment and HCV treatment initiation within aÂsystematic screening program in HIV/HCV coinfected patients. Wiener Klinische Wochenschrift, 2018, 130, 105-114.	1.9	14
420	Thyroid hormone receptor Î²1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. Journal of Lipid Research, 2018, 59, 1610-1619.	4.2	14
421	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease â€" Impact of changes in allocation policy. Hpb, 2018, 20, 916-924.	0.3	14
422	Nonâ€invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver International, 2020, 40, 1713-1724.	3.9	14
423	Absence of Bsep/Abcb11 attenuates MCD dietâ€induced hepatic steatosis but aggravates inflammation in mice. Liver International, 2020, 40, 1366-1377.	3.9	14
424	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. Liver International, 2020, 40, 787-796.	3.9	14
425	A Fibrosisâ€Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1105-1116.	7.3	14
426	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatology International, 2021, 15, 922-933.	4.2	14
427	Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis. PLoS ONE, 2017, 12, e0183167.	2.5	14
428	Cholestatic syndromes. Current Opinion in Gastroenterology, 2001, 17, 242-256.	2.3	13
429	Cholestatic syndromes. Current Opinion in Gastroenterology, 2003, 19, 216-231.	2.3	13
430	Hepatocyte nuclear factor-4Î± and bile acids regulate human concentrative nucleoside transporter-1 gene expression. American Journal of Physiology - Renal Physiology, 2009, 296, G936-G947.	3.4	13
431	Imbalance of proâ€and antifibrogenic genes and bile duct injury in murine Schistosoma mansoni infectionâ€"induced liver fibrosis. Tropical Medicine and International Health, 2009, 14, 1418-1425.	2.3	13
432	When lightning strikes twice: The plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. Journal of Hepatology, 2009, 50, 633-635.	3.7	13

#	Article	IF	Citations
433	Bile Acids as Modulators of Gut Microbiota Linking Dietary Habits and Inflammatory Bowel Disease: A Potentially Dangerous Liaison. Gastroenterology, 2013, 144, 844-846.	1.3	13
434	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	1.5	13
435	Surveillance colonoscopy in Austria: Are we following the guidelines?. Endoscopy, 2018, 50, 119-127.	1.8	13
436	Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. PLoS ONE, 2018, 13, e0197695.	2.5	13
437	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. Wiener Klinische Wochenschrift, 2019, 131, 395-403.	1.9	13
438	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilsonâ€™s Disease. JHEP Reports, 2019, 1, 2-8.	4.9	13
439	High seroprevalence of antiâ€Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. Liver International, 2019, 39, 640-645.	3.9	13
440	PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. International Journal of Molecular Sciences, 2020, 21, 8711.	4.1	13
441	NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4+ T Cells. Frontiers in Immunology, 2020, 11, 579.	4.8	13
442	Hepatocyte specific expression of an oncogenic variant of Î²-catenin results in cholestatic liver disease. Oncotarget, 2016, 7, 86985-86998.	1.8	13
443	Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress. Drug Metabolism and Disposition, 2007, 35, 1694-1699.	3.3	12
444	Ischemia and Cholestasis: More Than (Just) the Bile Ducts!. Transplantation, 2008, 85, 1083-1085.	1.0	12
445	The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. Trials, 2015, 16, 328.	1.6	12
446	Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis. Molecular Pharmacology, 2017, 92, 401-413.	2.3	12
447	Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. International Journal of Molecular Sciences, 2018, 19, 1777.	4.1	12
448	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatology International, 2020, 14, 1093-1103.	4.2	12
449	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1619-1627.	2.8	12
450	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. Hepatology International, 2021, 15, 1160-1173.	4.2	12

#	Article	IF	Citations
451	Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in nonâ€alcoholic fatty liver disease. Journal of Cellular and Molecular Medicine, 2022, 26, 1206-1218.	3.6	12
452	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. Clinical Gastroenterology and Hepatology, 2023, 21, 978-987.e2.	4.4	12
453	Bilirubin Kinetic Modeling for Quantification of Extracorporeal Liver Support. Blood Purification, 2006, 24, 413-422.	1.8	11
454	Comparative Analysis and Modeling of the Severity of Steatohepatitis in DDC-Treated Mouse Strains. PLoS ONE, 2014, 9, e111006.	2.5	11
455	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. AIDS Patient Care and STDs, 2014, 28, 221-227.	2.5	11
456	Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice. BioMed Research International, 2016, 2016, 1-7.	1.9	11
457	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective caseâ€“control study. European Journal of Gastroenterology and Hepatology, 2017, 29, 309-316.	1.6	11
458	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound in Medicine and Biology, 2018, 44, 2578-2586.	1.5	11
459	Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 467-468.	2.8	11
460	Recent outbreaks of severe hepatitis A virus infections in Vienna. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 335-344.	2.9	11
461	Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surgery and Nutrition, 2021, 10, 610-622.	1.5	11
462	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Digestive and Liver Disease, 2022, 54, 500-508.	0.9	11
463	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. Journal of Gastroenterology, 2022, 57, 99-110.	5.1	11
464	The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. Hepatology, 2009, 50, 893-899.	7.3	10
465	Nuclear receptor ligands in therapy of cholestatic liver disease. Frontiers in Bioscience - Landmark, 2009, Volume, 4299.	3.0	10
466	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: New light on an old paradox. Hepatology, 2013, 57, 2106-2109.	7.3	10
467	Epidemiological Trends of Hepatocellular Carcinoma in Austria. Digestive Diseases, 2014, 32, 664-669.	1.9	10
468	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. Journal of Infectious Diseases, 2015, 211, 729-735.	4.0	10

#	Article	IF	Citations
469	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Molecular Endocrinology, 2015, 29, 1320-1333.	3.7	10
470	The trigger matters â€“ outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver International, 2016, 36, 1649-1656.	3.9	10
471	Endoscopic versus surgical management of biliary complications â€“ Outcome analysis after 1188 orthotopic liver transplantations. Digestive and Liver Disease, 2016, 48, 1323-1329.	0.9	10
472	The impact of hepatic steatosis on portal hypertension. PLoS ONE, 2019, 14, e0224506.	2.5	10
473	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. AIDS Patient Care and STDs, 2019, 33, 197-206.	2.5	10
474	On the Mechanisms of Biliary Flux. Hepatology, 2021, 74, 3497-3512.	7.3	10
475	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. Journal of Personalized Medicine, 2021, 11, 1264.	2.5	10
476	The â€˜Viennese epidemicâ€™ of acute HCV in the era of directâ€acting antivirals. Journal of Viral Hepatitis, 2022, 29, 385-394.	2.0	10
477	ILâ€31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology, 2023, 77, 20-32.	7.3	10
478	Animal models of biliary tract injury. Current Opinion in Gastroenterology, 2012, 28, 239-243.	2.3	9
479	Serum bile acids in patients with hepatopulmonary syndrome. Zeitschrift Fur Gastroenterologie, 2017, 55, 361-367.	0.5	9
480	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wiener Klinische Wochenschrift, 2017, 129, 517-526.	1.9	9
481	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2164-2172.	2.8	9
482	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Reports, 2020, 2, 100060.	4.9	9
483	Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158730.	2.4	9
484	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. FASEB Journal, 2021, 35, e21217.	0.5	9
485	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. Clinical Gastroenterology and Hepatology, 2023, 21, 90-102.e6.	4.4	9
486	Ursodeoxycholic Acid for Treatment of Fatty Liver Disease and Dyslipidemia in Morbidly Obese Patients. Digestive Diseases, 2011, 29, 117-118.	1.9	8

#	Article	IF	Citations
487	Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. Digestion, 2015, 91, 286-293.	2.3	8
488	A pilot study of the endomicroscopic assessment of tumor extension in Barrettâ€™s esophagusâ€“associated neoplasia before endoscopic resection. Endoscopy International Open, 2015, 03, E19-E28.	1.8	8
489	Longâ€term followâ€up of ribavirinâ€free <scp>DAA</scp>â€based treatment in <scp>HCV</scp> recurrence after orthotopic liver transplantation. Liver International, 2018, 38, 1188-1197.	3.9	8
490	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. Digestive Diseases and Sciences, 2019, 64, 3642-3651.	2.3	8
491	Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research. BMC Health Services Research, 2019, 19, 920.	2.2	8
492	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2020, 12, 2961.	3.7	8
493	Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?. Nutrients, 2020, 12, 765.	4.1	8
494	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Hepatology Communications, 2021, 5, 1939-1952.	4.3	8
495	Proteomic Changes of Activated Hepatic Stellate Cells. International Journal of Molecular Sciences, 2021, 22, 12782.	4.1	8
496	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. Journal of Hepatology, 2022, 77, 1005-1013.	3.7	8
497	Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. American Journal of Gastroenterology, 1998, 93, 1985-1986.	0.4	7
498	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 2879-2885.	2.4	7
499	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	7
500	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterology Journal, 2019, 7, 651-661.	3.8	7
501	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
502	Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases. Journal of Autoimmunity, 2021, 119, 102610.	6.5	7
503	New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. United European Gastroenterology Journal, 2021, 9, 947-954.	3.8	7
504	Modern imaging of cholangitis. British Journal of Radiology, 2021, 94, 20210417.	2.2	7

#	Article	IF	Citations
505	Direct patient-physician communication via aÂhepatitisÂC hotline facilitates treatment initiation in patients with poor adherence. Wiener Klinische Wochenschrift, 2021, 133, 452-460.	1.9	7
506	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1485-1493.	3.7	7
507	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. Journal of Personalized Medicine, 2022, 12, 239.	2.5	7
508	Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2â^'/â^' mouse model of sclerosing cholangitis via immunomodulatory effects. Hepatology Communications, 2022, 6, 2368-2378.	4.3	7
509	Hepatocellular Bile Salt Transport: Lessons from Cholestasis. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 99D-104D.	1.7	6
510	Cholestatic syndromes. Current Opinion in Gastroenterology, 2002, 18, 314-329.	2.3	6
511	Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans. Digestion, 2012, 86, 244-249.	2.3	6
512	Hepatobiliary transporter expression and postâ€operative jaundice in patients undergoing partial hepatectomy. Liver International, 2012, 32, 119-127.	3.9	6
513	Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis. Clinical Liver Disease, 2017, 9, 43-47.	2.1	6
514	Hepatocyte specific expression of an oncogenic variant of Î²-catenin results in lethal metabolic dysfunction in mice. Oncotarget, 2018, 9, 11243-11257.	1.8	6
515	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. Scientific Reports, 2019, 9, 11674.	3.3	6
516	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Digestive and Liver Disease, 2020, 52, 1473-1479.	0.9	6
517	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. Annals of Internal Medicine, 2021, 174, 139-140.	3.9	6
518	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatology Communications, 2022, 6, 2569-2580.	4.3	6
519	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. Antiviral Therapy, 2014, 19, 407-414.	1.0	5
520	Sulphatation Does Not Appear to Be a Protective Mechanism to Prevent Oxysterol Accumulation in Humans and Mice. PLoS ONE, 2013, 8, e68031.	2.5	5
521	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. Journal of Pharmaceutical Sciences, 2016, 105, 106-112.	3.3	5
522	Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?. Hepatology, 2017, 65, 1758-1761.	7.3	5

#	Article	IF	Citations
523	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Oncotarget, 2017, 8, 57109-57120.	1.8	5
524	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. Journal of Visualized Experiments, 2018, , .	0.3	5
525	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. Cellular and Molecular Life Sciences, 2019, 76, 4391-4404.	5.4	5
526	Management of patients with chronic hepatitis C failing repeated courses of interferonâ€free direct acting antiviral combination therapy. GastroHep, 2019, 1, 76-83.	0.6	5
527	Alphaâ€fetoproteinâ€adjustedâ€toâ€HCCâ€size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterology Journal, 2021, 9, 209-219.	3.8	5
528	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. Journal of Personalized Medicine, 2021, 11, 281.	2.5	5
529	Recent advances in the understanding and management of hepatorenal syndrome. Faculty Reviews, 2021, 10, 48.	3.9	5
530	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 5693-5703.	2.3	5
531	The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation. Frontiers in Immunology, 2021, 12, 750466.	4.8	5
532	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Digestive Diseases and Sciences, 2020, 65, 2712-2718.	2.3	4
533	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. Journal of Hepatology, 2020, 73, S105.	3.7	4
534	Prevalence of antiâ€Hepatitis E antibodies and impact on disease severity in nonâ€alcoholic fatty liver disease. Hepatology Research, 2021, 51, 69-79.	3.4	4
535	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wiener Klinische Wochenschrift, 2021, 133, 421-431.	1.9	4
536	Characterization of endogenous bile acid composition in individuals with cold-activated brown adipose tissue. Molecular and Cellular Endocrinology, 2021, 536, 111403.	3.2	4
537	KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells. Journal of Lipid Research, 2022, 63, 100173.	4.2	4
538	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Advances in Medical Sciences, 2022, 67, 154-162.	2.1	4
539	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2006, 118, 769-775.	1.9	3
540	Animal Models of Cholestasis. , 2013, , 331-349.		3

#	Article	IF	Citations
541	A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors. Gastrointestinal Endoscopy, 2016, 84, 924-929.	1.0	3
542	[11C]acetate PET as a tool for diagnosis of liver steatosis. Abdominal Radiology, 2018, 43, 2963-2969.	2.1	3
543	THU-023-Monoacylglycerol lipase inhibition protects from hepatic inflammation and fibrosis in mouse models of sclerosing cholangitis. Journal of Hepatology, 2019, 70, e170.	3.7	3
544	In Vivo1H MRSpectroscopy of Biliary Components of Human Gallbladder at 7T. Journal of Magnetic Resonance Imaging, 2021, 53, 98-107.	3.4	3
545	Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. International Journal of Molecular Sciences, 2021, 22, 2126.	4.1	3
546	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. Liver International, 2021, 41, 2622-2634.	3.9	3
547	Cholestatic syndromes. Current Opinion in Gastroenterology, 1999, 15, 217-228.	2.3	3
548	Alterations of hepatobiliary transporter expression in primary biliary cirrhosis (PBC). Journal of Hepatology, 2002, 36, 28-29.	3.7	2
549	Mycosis as a Cause of Secondary Sclerosing Cholangitis Requiring Liver Retransplantation. Transplantation, 2011, 91, e14-e16.	1.0	2
550	Chromosomal instability in HCC: a key function for checkpoint kinase 2. Gut, 2018, 67, 204-205.	12.1	2
551	Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorusâ€31 Magnetic Resonance Spectroscopy Pilot Study. Journal of Magnetic Resonance Imaging, 2021, , .	3.4	2
552	Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease, 2022, 54, 1222-1229.	0.9	2
553	Abnormal hepatic sinusoidal bile acid transport: New insights into the pathogenesis of cholestasis?. Gastroenterology, 2001, 120, 321-322.	1.3	1
554	Editorial for â€˜Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosisâ€™. Liver International, 2014, 34, 328-329.	3.9	1
555	Reply. Hepatology, 2016, 63, 346-347.	7.3	1
556	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease, 2016, 48, 1194-1199.	0.9	1
557	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. Wiener Klinische Wochenschrift, 2016, 128, 414-420.	1.9	1
558	Effective medical treatments for PSC needed ASAP - is AESOP the answer?. Journal of Hepatology, 2020, 73, 12-14.	3.7	1

#	Article	IF	Citations
559	Acquired Alterations of Transporter Expression and Function in Cholestasis. , 2004, , 266-288.		1
560	Cholestatic syndromes. Current Opinion in Gastroenterology, 2000, 16, 239-250.	2.3	0
561	A4.6â€...Effects of Cholic Acid and its Derivatives in Experimental Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A25.2-A26.	0.9	0
562	Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth,Clostridium difficileinfection and polymyalgia rheumatica. BMJ Case Reports, 2016, 2016, bcr2015213465.	0.5	0
563	IDDF2019-ABS-0131â€...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
564	IDDF2019-ABS-0133â€...Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
565	EASL Recognition Award Recipient 2020: Prof. James L. Boyer. Journal of Hepatology, 2020, 73, 487-489.	3.7	0
566	Reply. Hepatology, 2020, 72, 1498-1499.	7.3	0
567	Reply to: â€œChallenges in understanding the consequences of variants in ABCB4 geneâ€. Journal of Hepatology, 2021, 74, 244-245.	3.7	0
568	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. Digestive and Liver Disease, 2021, 53, 345-352.	0.9	0
569	PrimÃr biliÃre Cholangitis (PBC). , 2021, , 368-376.		0
570	O24â€...Durability of obeticholic acid response in PBC patients who did not achieve poise trial criteria. , 2021, , .		0
571	Alan Hofmann (1931â€2021): A career well spent understanding bile acids. Hepatology, 2022, 75, 238-239.	7.3	0
572	A life with bile acids: Alan F. Hofmann (1931-2021). Journal of Hepatology, 2021, 75, 1265-1266.	3.7	0
573	Bile Acids and Their Receptors. , 2010, , 317-332.		0
574	HepatobiliÃre FunktionsstÃ¶rungen und Leberversagen. , 2011, , 567-578.		0
575	Primary Sclerosing Cholangitis (PSC). , 2014, , 301-316.		0
576	Bile Acids and Bilirubin in Liver Immunology. , 2020, , 103-124.		0

#	Article	IF	Citations
577	S0984â€ƒLong-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. American Journal of Gastroenterology, 2020, 115, S501-S502.	0.4	0
578	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors. , 0, , 275-300.		0
579	Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. Journal of Clinical Medicine, 2022, 11, 2863.	2.4	0